Minneapolis Heart Institute Foundation
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1982-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://mplsheart.org/
Clinical Trials
27
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
Secondary Mitral Regurgitation Treatment With MitraClip and Assessment by Cardiac Magnetic Resonance
- Conditions
- Heart Failure and Reduced Ejection FractionFunctional Mitral Regurgitation
- First Posted Date
- 2025-08-20
- Last Posted Date
- 2025-08-20
- Lead Sponsor
- Minneapolis Heart Institute Foundation
- Target Recruit Count
- 125
- Registration Number
- NCT07131631
- Locations
- 🇺🇸
Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States
🇺🇸Mount Sinai Fuster Heart Hospital, New York, New York, United States
🇺🇸Sanger Heart and Vascular Institute, Charlotte, North Carolina, United States
DESIFOR-EXPAND (MHIF)
- Conditions
- Statin TherapyStatin Adverse ReactionStatin
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-02-03
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Minneapolis Heart Institute Foundation
- Target Recruit Count
- 100
- Registration Number
- NCT06804980
- Locations
- 🇺🇸
Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States
Impact of CTO PCI (Chronic Total Occlusion Percutaneous Intervention) on Regular Physical Activity
- Conditions
- Chronic Total OcclusionOcclusion
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Minneapolis Heart Institute Foundation
- Target Recruit Count
- 1
- Registration Number
- NCT05440084
- Locations
- 🇺🇸
Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
- Conditions
- Heart AttackEnlarged Heart
- Interventions
- Drug: SGLT-2 inhibitorsDrug: Placebo
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Minneapolis Heart Institute Foundation
- Target Recruit Count
- 81
- Registration Number
- NCT05305911
- Locations
- 🇺🇸
Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States
Native Coronary Artery Instead of SAphenous Vein Graft Intervention for Treatment of Significant Saphenous Vein Graft Lesions
- Conditions
- Target Vessel Failure in Saphenous Vein GraftsPercutaneous Coronary Intervention
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Minneapolis Heart Institute Foundation
- Target Recruit Count
- 99
- Registration Number
- NCT05187351
- Locations
- 🇺🇸
Henry Ford Health System, Detroit, Michigan, United States
🇺🇸Minneapolis Heart Institute Foundation, MInneapolis, Minnesota, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next